Means and methods for diagnosing heart failure in a subject
AssigneesMetanomics GmbH, Rupreht-Karls-Universität Heidelberg
InventorsJens Fuhrmann, Regina Reszka, Jürgen Kastler, Kristina Busch, Edgar Leibold, Hugo Katus, Norbert Frey, Johanna Wolf, Tanja Weis
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject, a method for identifying whether a subject is in need for a therapy of heart failure or a method for determining whether a heart failure therapy is successful. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.
Claims14
A method for diagnosing heart failure in a subject comprising:
- a) detecting in a sample of a subject suspected to suffer from heart failure, but not exhibiting heart failure symptoms as described according to New York Heart Association class IV, the amount of at least one biomarker selected from the group consisting of cholesterylester C18:1 and cholesterylester C18:2, wherein the sample is a plasma or serum sample;
- b) pre-treating the sample using an extraction step prior to detecting the amount of the at least one biomarker
- c) comparing the amount of said at least one biomarker to a reference, whereby heart failure is to be diagnosed
- i) if the amount of said at least one biomarker is significantly decreased as compared to the reference when the reference is derived from a subject or group of subjects known not to suffer from heart failure or is a calculated reference;
- or
- ii) if the amount of said at least one biomarker is essentially identical to the reference when the reference is derived from a subject or group of subjects known to suffer from heart failure.
A method for determining whether a therapy against heart failure is successful in a subject receiving heart failure therapy comprising the steps of:
- a) detecting in a sample of a subject suspected to suffer from heart failure and who is recieving one or more heart failure therapies the amount of at least one biomarker selected from the group consisting of cholesterylester C18:1 and cholesterylester C18:2, wherein the sample is a plasma or serum sample;
- b) comparing the amount of said at least one biomarker to a reference,
- whereby heart failure is to be diagnosed
- i)if the amount of said at least one biomarker is significantly decreased as compared to the reference when the reference is derived from a subject or group of subjects known not to suffer from heart failure or is a calculated reference;
- or
- ii) if the amount of said at least one biomarker is essentially identical to the reference when the reference is derived from a subject or group of subjects known to suffer from heart failure;
- c) determining that a therapy is successful if no heart failure is diagnosed.
Dependencies are inferred from the claim text.